Kelun Pharmaceutical released its 2026 interim report, showing first-half net profit attributable to the parent of 1.13 billion yuan, up 12.7% year on year. Operating revenue was 8.84 billion yuan, down 2.7% year on year. Net profit attributable to the parent after deducting non-recurring items was 699 million yuan, down 29.0% year on year. Net cash flow from operating activities was 2.341 billion yuan, up 96.8% year on year. In the second quarter, net profit attributable to the parent was 674 million yuan, up 61.9% year on year, but net profit attributable to the parent after deducting non-recurring items was 318 million yuan, down 24.5% year on year. The company said that prices of some products declined due to the impact of centralized procurement policies, but increased sales revenue from innovative drugs and receipt of settlement income drove profit growth at Kelun-Biotech.
Sichuan Kelun-BiotechIncreased sales revenue from innovative drugs drove profit growth at Kelun-Biotech.
Sichuan Kelun Pharmaceutical Co LtdNet profit up 12.7% but non-recurring profit down 29%; mixed results with revenue decline and price cuts.
